The company is actively building a portfolio of both plant-derived and manufactured molecules that can address multiple areas of unmet medical needs.
CLINICAL TRIALS: Yes.
NEWS & PARTNERSHIPS:
2019
The company executed on several agreements with operators to grow and harvest industrial hemp under the terms and conditions of the Industrial Hemp Program developed by the Arizona Department of Agriculture.
Hyalolex, the company’s cannabinoid-based, non-FDA approved product designed to assist in helping improve the lives of patients suffering from Alzheimer’s disease and became available for purchase in select dispensaries in San Juan, Puerto Rico.
The company executed agreements with operators to grow and harvest industrial hemp under the terms and conditions of the Industrial Hemp Program developed by the Arizona Department of Agriculture.
2021
The company received patent #10,933,082 from the United States Patent and Trademark Office for the company’s cannabinoid composition and method for treating pain in patients with Psoriatic Arthritis, Fibromyalgia, Scleroderma and other conditions.
The company received patent #11,065,225 for the treatment of Alzheimer’s disease entitled “Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Disease.”
2022
The company acquired exclusive rights to a potential Alzeheimer’s drug development candidate through an IP license agreement.
The company received US Patent #11,351,152 titled “Method and Composition for Treating Seizure Disorders.”
2023
The Divisional Direction of Patents, Mexico, has issued a Granting Office Action for its treatment of Alzheimer’s disease titled “Method and Composition for Treating CNS Disorder.”
The company announced an artificial intelligence collaboration with Los Andes University’s Center for Research and Training in artificial intelligence. The partnership aims to leverage Generative AI to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of treatments to patients.
The company received European Patent No. 3193862 by the European Patent Office: “Cannabinoid Composition and Method for Treating Pain.”
The company received European Patent No. 3193862 by the European Patent Office for its innovative cannabis pain treatment which uses a cream base infused with a unique blend of cannabinoids including THC and CBD and is designed for transdermal absorption.
2025
The company introduced MINT-AD, Multimodal Interpretable Transformer for Alzheimer’s Disease, a platofrm used for the prediction of Alzheimer’s risk and to accelerate early detection. The platform uses data sources such as brain scans, genetics, lifestyle and cognitive metrics. The latform is designed to be integrated into physician workflows to help improve early detection, care personalization and clinical trial enrollment.